Summary & Overview
HCPCS Level II A9579: Gadolinium MRI Contrast Injection, Per mL
HCPCS Level II code A9579 denotes an injection of a gadolinium-based magnetic resonance contrast agent, billed per milliliter. It is used to capture supply and drug administration costs tied to contrast-enhanced MRI procedures. Nationally, utilization of gadolinium contrast is clinically important for diagnostic accuracy across neurology, musculoskeletal, and oncologic imaging and has implications for cost accounting, inventory management, and payer coverage policies.
Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of typical billing and coding context for A9579, benchmark considerations for per-milliliter billing of contrast media, common payer coverage patterns, and clinical scenarios where gadolinium-enhanced MRI is routinely used. The publication highlights policy factors that affect reimbursement and documentation requirements, and provides context for coding consistency across outpatient radiology settings.
This summary is aimed at billing managers, compliance officers, and radiology administrators seeking a national perspective on code use, payer coverage scope, and the clinical role of gadolinium-based MRI contrast agents. Data not available in the input for payer-specific rates, associated taxonomies, or ICD-10 mappings is noted where applicable.
Billing Code Overview
HCPCS Level II code A9579 describes an injection of a gadolinium-based magnetic resonance contrast agent, not otherwise specified (NOS), billed per milliliter. This code represents the administered contrast material used to enhance MRI imaging.
Service type: Contrast agent administration for magnetic resonance imaging (MRI)
Typical site of service: Hospital outpatient radiology departments, ambulatory imaging centers, and freestanding MRI clinics
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient radiology center for a contrast-enhanced magnetic resonance imaging (MRI) study to evaluate suspected intracranial pathology. The patient is a 58-year-old with new-onset headaches and a focal neurologic deficit. The ordering physician requests a brain MRI with contrast to characterize a suspected mass lesion identified on prior non-contrast imaging. The clinical workflow includes pre-procedure screening for renal function (serum creatinine and estimated glomerular filtration rate), allergy history, and informed consent for administration of a gadolinium-based contrast agent. On the day of service, the MRI technologist confirms identity and IV access, the radiology nurse or technologist prepares the contrast syringe, documents the volume in milliliters, and the radiologist or qualified physician supervises or personally administers the injection as required by facility policy. The billed supply is the gadolinium contrast agent per milliliter captured under A9579. Post-injection, the MRI sequences are acquired, images are interpreted by the radiologist, and the contrast volume used is recorded in the procedure note and supply documentation for accurate billing and inventory control.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug not administered; no wastage | Use when the contrast agent is ordered but not administered and no portion was used. |